Cargando…

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

Detalles Bibliográficos
Autores principales:	Barratt, Jonathan, Rovin, Brad, Diva, Ulysses, Mercer, Alex, Komers, Radko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933476/ https://www.ncbi.nlm.nih.gov/pubmed/31891005 http://dx.doi.org/10.1016/j.ekir.2019.08.007

Ejemplares similares

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023)

Why Target the Gut to Treat IgA Nephropathy?
por: Barratt, Jonathan, et al.
Publicado: (2020)

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
por: Floege, Jürgen, et al.
Publicado: (2022)

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

IgA nephropathy: a perspective for 2021
por: Floege, Jürgen, et al.
Publicado: (2021)

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy
por: Negrea, Lavinia, et al.
Publicado: (2021)

New insights into the pathogenesis of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2017)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

New strategies and perspectives on managing IgA nephropathy
por: Selvaskandan, Haresh, et al.
Publicado: (2019)

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
por: Trachtman, Howard, et al.
Publicado: (2023)

Challenges in IgA Nephropathy Management: An Era of Complement Inhibition
por: Tesař, Vladimir, et al.
Publicado: (2023)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
por: Scionti, Katrin, et al.
Publicado: (2021)

Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change Disease
por: Cho, Won-Hee, et al.
Publicado: (2020)

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
por: Komers, Radko, et al.
Publicado: (2020)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix
por: Taylor, Scott, et al.
Publicado: (2020)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
por: Cheung, Chee Kay, et al.
Publicado: (2021)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020)

Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy
por: Graham-Brown, M. P., et al.
Publicado: (2019)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
por: Pawluczyk, Izabella Z. A., et al.
Publicado: (2021)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Pyomyositis in a Patient with IgA Nephropathy and Kidney Transplant
por: Xipell, M., et al.
Publicado: (2019)

IgA nephropathy and kidney transplantation according to the Oxford classification
por: Vasconcelos, André de Sá, et al.
Publicado: (2023)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study
por: Jäger, Cédric, et al.
Publicado: (2022)

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease
por: Komers, Radko, et al.
Publicado: (2016)

Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy
por: Szeto, Cheuk-Chun, et al.
Publicado: (2020)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_m5iqaht26t26is59v1obditnt6